Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasmodia express two threonine-peptidase complexes during asexual development.

Benjamin Mordmüller1, Rolf Fendel, Andrea Kreidenweiss

  • 1University of Tübingen, Department of Parasitology, Germany. benjamin.mordmueller@uni-tuebingen.de

Molecular and Biochemical Parasitology
|April 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Epidemiology of Skin-Dwelling Filariae and Risk Factors for Mansonella streptocerca Infection, Gabon.

Emerging infectious diseases·2026
Same author

Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections.

PLoS pathogens·2026
Same author

Diagnostic accuracy of plasma cell-free DNA qPCR for Schistosoma haematobium assessed by Bayesian latent class analysis in a cohort of pregnant women from Lambaréné, Gabon.

Infectious diseases of poverty·2026
Same author

Reversal of Chloroquine Resistance in <i>Plasmodium falciparum</i> in Gabon: A Phenotype-Genotype Relationship over the Last 20 Years.

International journal of molecular sciences·2026
Same author

Polymorphic marker regions support divergence of Mansonella sp. "DEUX" and M. perstans.

Parasites & vectors·2026
Same author

Correction: Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression.

PLoS pathogens·2026

The proteasome and PfhslV are key threonine-peptidases in Plasmodium falciparum. Inhibiting the proteasome with epoxomicin leads to parasite death, offering a new antimalarial drug strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Parasitology

Background:

  • Threonine-peptidases, like the proteasome, are crucial multi-subunit enzymes in eukaryotes, regulating protein turnover and cellular processes.
  • Bacteria typically have ClpQ/hslV, a simpler T1-family peptidase, but Plasmodium falciparum uniquely possesses both proteasomal subunits and a ClpQ/hslV ortholog (PfhslV).
  • The structure, expression, and function of these peptidase complexes in P. falciparum remain largely uncharacterized.

Purpose of the Study:

  • To analyze the coding sequences and derived proteins of both proteasomal and PfhslV peptidase complexes in P. falciparum.
  • To investigate the expression patterns and functional roles of these enzymes within the parasite.
  • To identify potential drug targets for novel antimalarial therapies.

Main Methods:

Related Experiment Videos

  • Bioinformatic analysis of coding sequences for proteasomal and PfhslV subunits.
  • Expression analysis of PfhslV and proteasome during the P. falciparum cell cycle.
  • Treatment of P. falciparum with the threonine-peptidase inhibitor epoxomicin to assess effects on parasite viability and protein ubiquitination.

Main Results:

  • The proteasome is expressed throughout the P. falciparum cell cycle.
  • PfhslV expression is restricted to schizonts and merozoites.
  • Epoxomicin treatment inhibited proteasome activity, causing ubiquitinated protein accumulation and leading to parasite death.

Conclusions:

  • This study provides the first functional characterization of Plasmodium threonine-peptidase complexes.
  • The proteasome is essential for parasite survival and represents a promising target for antimalarial drug development.
  • Epoxomicin demonstrates potential as a lead compound for a new class of antimalarial drugs targeting parasite proteases.